SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads - Concepedia

Concepedia

Publication | Closed Access

SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads

81

Citations

44

References

2018

Year

Krista Kinneer, John Meekin, Arnaud Tiberghien, Yu‐Tzu Tai, Sandrina Phipps, Christine Mione Kiefer, Marlon C. Rebelatto, Nazzareno Dimasi, Alyssa Moriarty, Kyriakos P. Papadopoulos,

Clinical Cancer Research

Abstract

Our findings support <i>SLC46A3</i> as a potential patient selection biomarker with immediate relevance to clinical trials involving these ADCs.

References

	Year	Citations

Page 1